Literature DB >> 184819

Enzymatic synthesis of (15s)-[15-3h]prostaglandins and their use in the development of a simple and sensitive assay for 15-hydroxyprostaglandin dehydrogenase.

H H Tai.   

Abstract

The stereospecificity of swine renal NAD+-dependent 15-hydroxyprostaglandin dehydrogenase has been determined. It was found that the enzyme is a B-side specific dehydrogenase. (15S)-[15-3H]Prostaglandins were synthesized by stereospecific transfer of the tritium label of D-[1-3H]galactose to prostaglandins by coupling 15-hydroxyprostaglandin dehydrogenase with beta-D-galactose dehydrogenase, an enzyme of the same stereospecificity. A simple and sensitive assay for 15-hydroxyprostaglandin dehydrogenase was developed based on the stereospecific transfer of the tritium label of tritiated prostaglandins to glutamate by coupling 15-hydroxyprostaglandin dehydrogenase with glutamate dehydrogenase. The amount of prostaglandin oxidized is determined by the radioactivity of labeled glutamate present in the supernatant after charcoal precipitation of labeled prostaglandin. Concurrent assays with the present tritium release method and the thin-layer chromatography method indicated excellent correlation. The assay was employed to study some of the properties of swine renal 15-hydroxyprostaglandin dehydrogenase in crude extract and the distribution of enzyme activity in various tissues of rat. Enzyme activity was linear for the first 10 min studied and was nonlinear with increasing amounts of crude enzyme, indicating the possible presence of endogenous inhibitor(s). Apparent Km's for PGE2, PGF2alpha, and PGA2 were found to be 2.5, 12.5, and 3.9 muM, respectively. The distribution pattern indicated high levels of enzyme activity in gastrointestinal tract, lung, kidney, and spleen. The assay method may prove to be valuable for studying enzyme turnover and enzyme regulation by hormonal and pharmacological agents.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 184819     DOI: 10.1021/bi00666a007

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Purification, cDNA cloning and expression of 15-oxoprostaglandin 13-reductase from pig lung.

Authors:  C M Ensor; H Zhang; H H Tai
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

2.  Monoclonal antibodies that inhibit the enzyme activity of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase.

Authors:  C L Tai; O T Mak; T Arai; H H Tai
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

3.  15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Authors:  Min Yan; Ronald M Rerko; Petra Platzer; Dawn Dawson; Joseph Willis; Min Tong; Earl Lawrence; James Lutterbaugh; Shilong Lu; James K V Willson; Guangbin Luo; Jack Hensold; Hsin-Hsiung Tai; Keith Wilson; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

4.  Stimulation of synthesis de novo of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase in human promyelocytic leukaemia (HL-60) cells by phorbol ester.

Authors:  C Q Xun; Z G Tian; H H Tai
Journal:  Biochem J       Date:  1991-10-15       Impact factor: 3.857

5.  15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.

Authors:  Michael G Backlund; Jason R Mann; Vijaykumar R Holla; F Gregory Buchanan; Hsin-Hsiung Tai; Erik S Musiek; Ginger L Milne; Sharada Katkuri; Raymond N DuBois
Journal:  J Biol Chem       Date:  2004-11-12       Impact factor: 5.157

6.  Regional differences in prostaglandin E₂ metabolism in human colorectal cancer liver metastases.

Authors:  Alastair L Young; Claire R Chalmers; Gillian Hawcroft; Sarah L Perry; Darren Treanor; Giles J Toogood; Pamela F Jones; Mark A Hull
Journal:  BMC Cancer       Date:  2013-02-26       Impact factor: 4.430

7.  Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer.

Authors:  Milene Volpato; Michele Cummings; Abeer M Shaaban; Balkees Abderrahman; Mark A Hull; Philipp Y Maximov; Bradley M Broom; Reiner Hoppe; Ping Fan; Hiltrud Brauch; V Craig Jordan; Valerie Speirs
Journal:  Explor Target Antitumor Ther       Date:  2020-10-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.